|  | 
| Mechanism5-HT6 receptor antagonists | 
|  | 
|  | 
|  | 
|  | 
| Drug Highest PhaseApproved | 
| First Approval Ctry. / Loc.China | 
| First Approval Date01 Jan 1996 | 
 / Not yet recruitingPhase 2 Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic  Non-Small Cell Lung Cancer (NSCLC), EGFR wild type - SCI-Ta1-NSCLC-CHEMO P2-001
100 Clinical Results associated with Sciclone Pharmaceuticals Italy Srl
0  Patents (Medical) associated with Sciclone Pharmaceuticals Italy Srl
100 Deals associated with Sciclone Pharmaceuticals Italy Srl
100 Translational Medicine associated with Sciclone Pharmaceuticals Italy Srl